NeOnc Technologies Announces Updated Results From Phase 1/2a And Compassionate-Use Experience Of NEO100; Says Updated Results Demonstrate Radiographic Remission In 6 Of 25 Patients

Updated results demonstrate that treatment with intranasally delivered NEO100 has resulted in significant radiographic remission in 6 of 25 patients (24%), representing 3X increase over the 8% response rates typically reported with salvage therapies in recurrent high-grade gliomas.

Additionally, 44% of patients achieved six-month progression-free survival (PFS-6), exceeding historical benchmarks of 21–31% for IDH1-mutant recurrent high-grade gliomas. Importantly, 9 of 25 patients (36%) remain alive ≥18 months following initiation of NEO100, providing further evidence of meaningful long-term survival in this heavily pretreated population.

No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged and chronic dosing.